172 related articles for article (PubMed ID: 1375841)
1. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
[TBL] [Abstract][Full Text] [Related]
3. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
4. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
[TBL] [Abstract][Full Text] [Related]
5. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
6. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
Ek O; Gaynon P; Zeren T; Chelstrom LM; Myers DE; Uckun FM
Leuk Lymphoma; 1998 Sep; 31(1-2):143-9. PubMed ID: 9720724
[TBL] [Abstract][Full Text] [Related]
7. Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
Ek O; Reaman GH; Crankshaw DL; Chelstrom LM; Myers DE; Uckun FM
Leuk Lymphoma; 1998 Feb; 28(5-6):509-14. PubMed ID: 9613980
[TBL] [Abstract][Full Text] [Related]
8. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
Messinger Y; Yanishevski Y; Avramis VI; Ek O; Chelstrom LM; Gunther R; Myers DE; Irvin JD; Evans W; Uckun FM
Clin Cancer Res; 1996 Sep; 2(9):1533-42. PubMed ID: 9816330
[TBL] [Abstract][Full Text] [Related]
9. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
[TBL] [Abstract][Full Text] [Related]
10. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
Myers DE; Uckun FM
Leuk Lymphoma; 1995 Jun; 18(1-2):119-22. PubMed ID: 8580813
[TBL] [Abstract][Full Text] [Related]
11. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
Myers DE; Irvin JD; Smith RS; Kuebelbeck VM; Uckun FM
J Immunol Methods; 1991 Feb; 136(2):221-37. PubMed ID: 1705571
[TBL] [Abstract][Full Text] [Related]
12. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
Messinger Y; Reaman GH; Ek O; Uckun FM
Leuk Lymphoma; 1999 Apr; 33(3-4):289-93. PubMed ID: 10221508
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells.
Waddick KG; Myers DE; Gunther R; Chelstrom LM; Chandan-Langlie M; Irvin JD; Tumer N; Uckun FM
Blood; 1995 Dec; 86(11):4228-33. PubMed ID: 7492781
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin.
Jansen B; Uckun FM; Jaszcz WB; Kersey JH
Cancer Res; 1992 Jan; 52(2):406-12. PubMed ID: 1370213
[TBL] [Abstract][Full Text] [Related]
16. Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Gunther R; Chelstrom LM; Wendorf HR; Schneider EA; Covalciuc K; Johnson B; Clementson D; Irvin JD; Myers DE; Uckun FM
Leuk Lymphoma; 1996 Jun; 22(1-2):61-70, follow.186, color plate II-V. PubMed ID: 8724529
[TBL] [Abstract][Full Text] [Related]
17. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
Uckun FM; Haissig S; Ledbetter JA; Fidler P; Myers DE; Kuebelbeck V; Weisdorf D; Gajl-Peczalska K; Kersey JH; Ramsay NK
Blood; 1992 Jun; 79(12):3369-79. PubMed ID: 1375851
[TBL] [Abstract][Full Text] [Related]
18. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM
Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
[TBL] [Abstract][Full Text] [Related]
19. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
[TBL] [Abstract][Full Text] [Related]
20. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]